Befejeződött1. fázis
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)
Key facts
- Where
- Brescia, Candiolo, Milan és Ravenna, OlaszországSee the 5 sites
- Phase
- 1. fázis
Where in Olaszország
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, OlaszországNo longer taking part
- Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCSCandiolo, OlaszországNo longer taking part
- Istituto Europeo di Oncologia s.r.lMilan, OlaszországNo longer taking part
- Ospedale San Raffaele S.r.l.Milan, OlaszországNo longer taking part
- Azienda Unità Sanitaria Locale della RomagnaRavenna, OlaszországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Byondis B.V.
- Trial code
- EU 2024-512390-27-00
- Record updated
- 2026. április 8.